Sleep Apnea Drug Breakthrough, PFAS Water Alert, and a Malaria Vaccine Milestone
A GLP-1 drug halves sleep apnea, WHO flags PFAS in Mediterranean water, and a malaria vaccine holds 77% efficacy at three years.
By Dr. Asher Knippel
The first day of September brings decisive clinical results, an urgent environmental-health warning, and a landmark infectious-disease milestone — alongside a seasonal advisory for Cyprus and the eastern Mediterranean.
Tirzepatide Cuts Obstructive Sleep Apnea Severity in Half in Landmark Phase-3 Trial
The SURMOUNT-OSA phase-3 trial, published this week in the New England Journal of Medicine, found that tirzepatide — Eli Lilly's dual GIP/GLP-1 receptor agonist — reduced apnea-hypopnea index (AHI, the standard measure of sleep apnea severity) by an average of 55% in participants with obesity and moderate-to-severe obstructive sleep apnoea, compared with 5% in the placebo group. Around 40% of participants in the tirzepatide arm achieved complete remission, defined as AHI below 5 events per hour. The trial enrolled 469 adults across 17 countries; no new safety signals were identified beyond the gastrointestinal effects typical of GLP-1-class drugs. The US FDA has granted tirzepatide a Priority Review designation for the OSA indication; a regulatory decision is expected in late 2026. Obstructive sleep apnea affects an estimated 1 billion people worldwide and remains dramatically underdiagnosed, particularly across the Mediterranean, where heat-disturbed sleep may mask or worsen symptoms.
WHO Raises Global Alarm on PFAS in Drinking Water; Mediterranean Aquifers Among Regions Flagged
The World Health Organization released an updated risk assessment on per- and polyfluoroalkyl substances (PFAS) — commonly called "forever chemicals" — in drinking water, identifying exceedances of the new WHO guideline (0.1 µg/L for PFOA equivalents) in samples from more than 40 countries. Mediterranean aquifers in southern Spain, Greece, and coastal Cyprus recorded elevated PFAS concentrations linked to decades of firefighting-foam use at airports and military installations; the assessment flags these as priority remediation sites. PFAS accumulate in the body and are associated with thyroid disruption, reduced vaccine response in children, and elevated risk of certain kidney and testicular cancers. WHO recommends activated-carbon or reverse-osmosis filtration for affected municipal supplies and urges national regulators to adopt the updated limits by 2027. Cyprus's Ministry of Health has initiated a national water-quality survey; preliminary results are expected by year end.
Oxford's R21/Matrix-M Malaria Vaccine Sustains 77% Efficacy at Three-Year Follow-Up
A three-year follow-up analysis of the Oxford–Serum Institute R21/Matrix-M phase-3 trial, published in The Lancet, confirms approximately 77% efficacy against clinical malaria in children aged 5 to 36 months at trial sites in Burkina Faso, Kenya, Mali, and Tanzania. A booster-dose schedule — primary series plus annual top-ups — sustained protection without meaningful waning in year three, a notable improvement over the older RTS,S/AS01 (Mosquirix) vaccine, which showed progressive efficacy decline after the second year. The WHO has already recommended R21/Matrix-M for broad use in high-burden countries in sub-Saharan Africa; GAVI has committed to procuring 40 million doses per year from 2027. Malaria kills approximately 600,000 people annually, with children under five bearing the greatest toll.
Novel Anti-Inflammatory Antibody Achieves 68% Remission in Treatment-Resistant Depression
A phase-3 multicentre trial published this week reports that an investigational monoclonal antibody targeting the IL-6 signalling pathway reached 68% remission in adults with treatment-resistant depression (TRD) — defined as failure of at least two adequate antidepressant courses — compared with 23% in the placebo arm. The biologic was developed in collaboration with the US National Institute of Mental Health and is premised on the observation that a clinically identifiable subset of TRD patients carry elevated neuroinflammatory markers; participants were pre-screened for raised CRP and IL-6 levels. Side-effects were mild; one case of reversible immunosuppression was observed across the 520-person trial. The FDA granted Breakthrough Therapy designation in January 2026; a regulatory submission is planned for the first quarter of 2027. Around 100 million people live with TRD globally; current second-line options such as ECT, intranasal ketamine, and repetitive TMS reach only a fraction of those who need them.
Oral Teplizumab Delays Type 1 Diabetes Onset by 5.4 Years in High-Risk Children
The PROTECT-2 trial, conducted across 28 paediatric diabetes centres in Europe and North America, found that oral low-dose teplizumab — an anti-CD3 monoclonal antibody — delayed clinical onset of type 1 diabetes by a median of 5.4 years in children aged 8 to 15 carrying two or more autoimmune risk markers (positive islet autoantibodies plus dysglycaemia). Earlier data from the injectable form of the drug showed a 2–3-year delay; the oral formulation appears more effective and is substantially easier to administer to children over a multi-year observation window. JDRF co-sponsored the trial in partnership with Sanofi; a European Medicines Agency marketing-authorisation application is under review. Type 1 diabetes affects roughly 9 million people worldwide, with peak onset in childhood; even a multi-year deferral of clinical diagnosis can preserve residual beta-cell function and simplify lifetime management.
ECDC and Cyprus MoH Issue Early-Autumn Influenza Vaccination Advisory
The European Centre for Disease Prevention and Control and Cyprus's Ministry of Health issued a joint advisory on 1 September urging influenza vaccination ahead of October, after WHO Mediterranean regional surveillance identified an H3N2 variant with partial antigenic distance from the Northern Hemisphere vaccine strain. While the 2026–27 Northern Hemisphere vaccine covers the dominant H3N2 lineage, early circulation data suggest potentially reduced effectiveness in adults aged 60 and over. High-risk groups — older adults, pregnant women, people with chronic cardiopulmonary disease, and immunocompromised individuals — are encouraged to be vaccinated in September rather than waiting until the traditional October window. Cyprus vaccination centres will accept seasonal flu vaccine bookings from 3 September; GeSY (the General Health System) covers the cost for eligible groups.
This article is a journalistic summary produced for informational purposes only and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management plan.